LXRX Dividend History & Analysis | N/A Yield
LXRX has a dividend yield of N/A and paid N/A per share in the last 12M. Complete payout history, full analyses and peer comparison.
Top Dividend Payers in Biotechnology
| Symbol | Market Cap USD | Dividend Yield TTM | Yield on Cost 5y |
|---|---|---|---|
| BTX | 1,406 M | 13.7% | 7.37% |
| ABBV | 406,304 M | 3.63% | 9.56% |
| AMGN | 179,831 M | 3.68% | 6.22% |
| GILD | 155,932 M | 2.57% | 6.37% |
| HLN | 45,108 M | 1.75% | 2.46% |
| Symbol | Market Cap USD | Growth Rate (CAGR) | Payout Consistency |
|---|---|---|---|
| BTX | 1,406 M | 134% | 91.7% |
| HLN | 45,108 M | 51.0% | 100% |
| AMGN | 179,831 M | 7.84% | 100% |
| ABBV | 406,304 M | 5.98% | 100% |
| GILD | 155,932 M | 2.74% | 100% |
Similar Stocks with Attractive Dividends - Compare LXRX Dividends with its Peer-Group
3.63% Yield
3.68% Yield
2.57% Yield
1.75% Yield
LXRX Dividend History: as of January 2026
No dividends paid yet.LXRX Dividend FAQ
Lexicon Pharmaceuticals (NASDAQ:LXRX) is a U.S.-based biotech that develops oral small-molecule therapies. Its lead asset, sotagliflozin, is an SGLT-1/2 inhibitor approved for reducing cardiovascular death, heart-failure hospitalizations, and urgent visits in patients with heart failure, type 2 diabetes, or chronic kidney disease. The pipeline includes sotagliflozin in Phase 3 for hypertrophic cardiomyopathy and type 1 diabetes, LX9211 (Phase II completed for neuropathic pain), and LX9851 (obesity and cardiometabolic risk). The company partners with Viatris and Bristol-Myers Squibb for commercialization and co-development.
What is the Dividend Yield of LXRX?
As of January 2026, LXRX`s dividend yield is %. This is calculated by dividing the trailing 12-month dividend rate (TTM rate) of - by the current share price of 1.15.Does LXRX pay a dividend?
As of January 2026 LXRX does not pay a dividend.How often does LXRX pay dividends?
Over the last 12 months, LXRX has issued dividend payments.LXRX dividend forecast
Based on historical data, the forecasted dividends per share for LXRX for the next 4 payments are between 0 (+0.0%) and 0 (+0.0%).This suggests the dividend will remain relatively stable.
Will LXRX pay dividends in 2026?
The next Ex-Dividend date for Lexicon Pharmaceuticals (LXRX) is currently unknown.What is the next Ex-Dividend Date for LXRX?
The next Ex-Dividend date for Lexicon Pharmaceuticals (LXRX) is currently unknown. We automatically update the next Ex-Dividend date when it is announced.What is the Dividend Growth of LXRX?
LXRX's average dividend growth rate over the past 5 years is -% per year.
What is the Yield on Cost of LXRX?
LXRX's 5-Year Yield on Cost is -%. If you bought LXRX's shares at 3.52 five years ago, your current annual dividend income (- per share, trailing 12 months) equals -% of your original purchase price.What is the Payout Consistency of LXRX?
LXRX Payout Consistency is 0.0%.
The payout consistency is a proprietary measure of how consistently a company has paid dividends over its lifetime and blends growth rate, number of dividend payments, interruptions or lowering dividends into one number.
Does LXRX have a good Dividend Yield?
LXRX`s % Dividend Yield is considered as unknown.What is the Dividend Payout Ratio of LXRX?
The Dividend Payout Ratio of LXRX is unknown.What is the Dividend Rating of LXRX?
LXRX`s Overall Dividend Rating is (unknown). Ratings surpassing 65% are regarded as acceptable, exceeding 75% are favorable and surpassing 85% are strong.Key Metric Definitions
- Dividend Yield: Annual dividend per share divided by current share price.
- Dividend Growth Rate: Compound annual growth rate of annual dividend per share over the last 5 years.
- Payout Ratio: Percentage of earnings paid as dividends (TTM).
- Payout Consistency: % of eligible periods with uninterrupted or increased dividends, measured over the entire lifetime of the stock or fund.
- Payout Frequency: Number of dividends paid in the last 12m (TTM).
- Overall Dividend Rating: Proprietary composite score, quantified on a scale from 0 to +100. Ratings surpassing 70 are regarded as favorable, while those exceeding 85 are strong.
- Total Return: Price appreciation plus dividends over specified period.
- Market Cap: Figures are in millions of the corresponding currency.
Last update: 2025-12-19 04:43